5 hrs ago
Eli Lilly and Price Target Increased to $60.00 by Analysts at Jefferies Group
The firm currently has a "hold" rating on the stock. Jefferies Group's price objective suggests a potential upside of 0.74% from the company's current price.
Trending on the Topix Network
20 hrs ago
Lincoln Daily News
Lilly eyes emerging markets in Novartis animal-health deal
The purchase of Novartis' animal-health business will strengthen Eli Lilly's hand in emerging markets, tapping into growing demand there for protein-rich diets and household treatments for pets, top executives of the U.S. company said.
Tue Apr 22, 2014
The Indianapolis Star
Eli Lilly's $5.4B acquisition will boost Elanco
Drug maker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Eli Lilly & Co.
Mon Apr 21, 2014
Eli Lilly to buy Novartis' animal health business for $5.4 bln
Eli Lilly and Co said on Tuesday it will buy Novartis AG's animal health business for $5.4 billion in cash to strengthen and diversify its Elanco unit.
The Indianapolis Star
FDA approves new Eli Lilly drug to treat stomach cancer
Eli Lilly and Co. corporate headquarters at Delaware and McCarty streets in Downtown Indianapolis.
Eli Lilly to Speak at Metabolomics Meeting, May 22-23 2014, Cambridge, MA
Cross-platform Omics Data Integration in Ingenuity Systems" at the Inaugural Metabolomics Conference - Advances & Applications in Human Disease to be held in Cambridge, MA on May 22-23, 2014 by GTCBio.
Tue Apr 15, 2014
Lilly Invests Millions On New Anti-Counterfeiting Serialization Program
Over the next two years, Eli Lilly will be strengthening its efforts against counterfeiting with a $110 million investment in a new serialization program for its drug packages.
Mon Apr 14, 2014
Boehringer Ingelheim and Eli Lilly Announce NDA Filing for Empagliflozin and Linagliptin Combination
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration accepted the filing of the New Drug Application for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes .
Wall Street Journal
Eli Lilly vs. Canada: The Patent War Moves to Washington
Its efforts underscore growing frustration the pharmaceutical industry has toward some foreign governments over patent rights, although much of the vitriol has often been directed toward India.
Eli Lilly and Upgraded to "Hold" by Jefferies
The firm currently has a $54.00 target price on the stock, up from their previous target price of $45.00.
Eli Lilly and PT Raised to $54.00
The firm currently has a "hold" rating on the stock. A number of other analysts have also recently weighed in on LLY.
Fri Apr 11, 2014
Lilly Confirms Date and Conference Call for First-Quarter 2014 Financial Results Announcement
Eli Lilly and Company will announce its financial results for the first quarter of 2014 on Thursday, April 24, 2014.
Thu Apr 10, 2014
Big News Network.com
Takeda and Eli Lilly to appeal $9bn punitive damages ordered by court
Our eNewspaper network was founded in 2002 to provide stand-alone digital news sites tailored for the most searched-for locations for news.
Indiana lawmakers weigh in on drug patent dispute
Indiana lawmakers want the Obama administration to increase pressure on Canada over the country's handling of pharmaceutical patents.
Biotech company's progress brings cash, new CEO
A Kansas biotech company said it has new money, and a new CEO, as one of its cancer treatment drugs progressed to Phase I clinical trials.
Wed Apr 09, 2014
The Japan Times
Pharmaceutical giant Takeda to fight $6 billion damages ruling by...
Takeda Pharmaceutical Co. said it would contest $6 billion in punitive damages imposed by a jury in the United States in a case that accused Japan's largest drugmaker of concealing cancer risks associated with its Actos diabetes drug.
Tue Apr 08, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
Johnson comes to Bizwom... )--A U.S. jury's combined $9 billion judgment against Japan's Takeda Pharmaceutical partner company Eli Lilly will not affect LLY's ratings, according to Fitch Ratings... )--FUND db x-trackers Stoxx Europe 600 Technology UCITS ETF DEALING DATE 7-Apr-14 NAV PER SHARE EUR39.7009 NUMBER OF SHARES IN ISSUE 310,533 CODE ... (more)
US jury hits Eli Lilly, Takeda with $9B penalty
Testifying in his murder trial on Tuesday, Oscar Pistorius said he and girlfriend Reeva Steenkamp sometimes had troubles in their relationship but that they sorted them out, were in love and were planning Testifying in his murder trial on Tuesday, Oscar Pistorius said he and girlfriend Reeva Steenkamp sometimes had troubles in their relationship ... (more)
Mon Apr 07, 2014
The Washington Post
Takeda, Lilly Jury Awards $9 Billion Over Hiding Actos Risks
Takeda Pharmaceutical Co. and Eli Lilly & Co. were ordered to pay a combined $9 billion after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.
Customer Interaction Solutions
Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120
Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its pan-RAF inhibitor LY3009120 , under development in collaboration with Eli Lilly.